bosutinib
Selected indexed studies
- Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. (Leukemia, 2023) [PMID:36717654]
- Bosutinib. (, 2012) [PMID:31643284]
- A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. (Blood, 2021) [PMID:34407542]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. (2023) pubmed
- A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. (2021) pubmed
- Bosutinib. (2012) pubmed
- Bosutinib. (2006) pubmed
- Bosutinib: Pediatric First Approval. (2024) pubmed
- Bosutinib. (2010) pubmed
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. (2018) pubmed
- Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. (2022) pubmed
- Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. (2025) pubmed
- Chronic Myeloid Leukemia: A Review. (2025) pubmed